Influenza viruses: Basic biology and potential drug targets
Influenza viruses: Basic biology and potential drug targets
复制标题
DOI：
10.2174/187152607783018745
复制
发表时间：
2007-12-01
影响因子：
--
通讯作者：
Basler, Christopher F.
中科院分区：
文献类型：
--
作者：
Basler, Christopher F.
甲型流感和B流感病毒每年都是导致发病和死亡的持续原因。历史上，甲型流感病毒在人群中引起周期性大流行，有时具有破坏性后果，例如1918年。近年来，由于高致病性H5N1禽流感病毒在鸟类中持续爆发，偶尔但往往致命地感染人类，对新的大流行病的担忧有所增加。尽管它们作为人类病原体的重要性，但批准用于治疗流感病毒感染的抗病毒药物目前仅限于两个靶点，即病毒神经氨酸酶和病毒离子通道M2。M2抑制剂金刚烷胺和金刚乙胺的使用进一步受到这些药物选择耐药变体的倾向的限制。然而，流感病毒的复制周期已被深入研究，并受到越来越多的关注。新的机会存在于开发针对这些病毒的新型抗病毒策略中。
Influenza A and influenza B viruses are continuing causes of morbidity and mortality on an annual basis. Influenza A viruses have historically caused periodic pandemics in the human population, sometimes with devastating consequences, such as in 1918. Fears of a new pandemic have increased in recent years because of continuing outbreaks of highly pathogenic H5N1 avian influenza viruses in birds with occasional, but often lethal infection of humans. Despite their importance as human pathogens, the antiviral drugs approved to treat influenza virus infections are currently limited to two targets, the viral neuraminidase and the viral ion channel, M2. The use of the M2 inhibitors amantadine and rimantadine is further limited by the propensity of these drugs to select for drug resistant variants. However, the replication cycle of influenza viruses has been intensively studied and is receiving increased attention. New opportunities exist to develop novel antiviral strategies targeting these viruses.